DoubleChecks

What was claimed

A new vaccine against pancreatic cancer... prompted an immune response in 99% of the patients whose responses could be measured... Patients with the strongest immune responses tended to remain cancer-free for longer

Our verdict

Accurate

Multiple sources confirm that in phase 2 trials, 99% of evaluable patients (89 out of 90) developed immune responses to KRAS-targeting vaccines. The phrasing 'whose responses could be measured' accurately reflects that this was among evaluable patients.

Combined assessment15 sourcesChecked Nov 2, 2026

Why this verdict

  • Patients with the strongest immune responses tended to remain cancer-free for longer.

    Supported
    All assessments reached this conclusion

  • A new vaccine against pancreatic cancer prompted an immune response in 99% of the patients whose responses could be measured.

    Supported
    Two assessments reached this conclusion; one differed·Perplexity: Can’t verify

Evidence reviewed

15 sources

Perplexity, Claude and ChatGPT sources are combined here.

nature.comnature.comnature.comnature.comnature.comnature.comoncodaily.comnature.comnature.comnature.com

Individual assessments

Assessment summary

  • The response combines findings from different pancreatic cancer vaccine studies.
  • The 99% figure is supported by a reported KRAS-vaccine study, but the strongest evidence available for that study describes 84% of patients mounting immune responses, not 99%.nature.com nature.com The claim that stronger responses were associated with longer cancer-free survival is supported, but the evidence is from early-phase studies and does not establish that the vaccine caused the benefit.nature.com nature.com

Claims reviewed

A new vaccine against pancreatic cancer prompted an immune response in 99% of the patients whose responses could be measured.

Can’t verify
A secondary report states a 99% response rate for a KRAS vaccine, but the published phase 1 study reports immune responses in 21 of 25 patients, or 84%.nature.com nature.com The specific 99% wording is therefore not confirmed by the strongest source available.

Patients with the strongest immune responses tended to remain cancer-free for longer.

Supported
The published study found that patients with above-median T-cell responses had longer recurrence-free survival, although the result was from an early-phase study and was not definitive.nature.com

Assessment summary

  • Both major claims are factually accurate based on recent clinical trial data.
  • The 99% immune response rate is well-documented in phase 2 trials, and the correlation between stronger immune responses and longer disease-free survival is supported by multiple sources.

Claims reviewed

Patients with the strongest immune responses tended to remain cancer-free for longer

Supported
Multiple clinical trial sources confirm this association. Patients with stronger immune responses had lower recurrence rates and longer disease-free survival times mskcc.org sciencealert.com curetoday.com. One source states 'patients with the strongest immune responses had dramatically lower recurrence rates.'

A new vaccine against pancreatic cancer prompted an immune response in 99% of the patients whose responses could be measured

Supported
Multiple sources confirm that in phase 2 trials, 99% of evaluable patients (89 out of 90) developed immune responses to KRAS-targeting vaccines mskcc.org sciencealert.com curetoday.com. The phrasing 'whose responses could be measured' accurately reflects that this was among evaluable patients.

Assessment summary

  • Reports from the recent phase 2/early trials state that about 99% (98.9%) of assessable vaccine recipients mounted a KRAS-specific T-cell response.
  • Exploratory analyses in those reports also found that patients who mounted the strongest immune responses tended to have longer recurrence-free or disease-free intervals.
  • These findings were described as immune-response (immunogenicity) outcomes and correlational clinical observations, not definitive proof of prevention or cure.

Claims reviewed

Patients with the strongest immune responses tended to remain cancer-free for longer.

Supported
Exploratory analyses in the trial publications and press materials report an association between stronger vaccine-induced T-cell responses and longer recurrence-free or disease-free survival, though the studies were small and not definitive. medicalxpress.com aacr.org

The vaccine prompted an immune response in 99% of the patients whose responses could be measured.

Supported
Published reports and press releases state that among assessable patients roughly 98.9%–99% developed KRAS-specific T-cell responses in the trial. sciencealert.com medicalxpress.com

Check your own claim

Paste any statement, headline, or AI answer. Independent assessments check it and compare sources.

Share this result